Details of the Drug
General Information of Drug (ID: DMZ6TRV)
| Drug Name |
5-phenyl-1,3,4-oxadiazole-2(3H)-thione
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
3004-42-0; 5-Phenyl-1,3,4-oxadiazole-2-thiol; 5-Phenyl-1,3,4-oxadiazole-2(3H)-thione; 1,3,4-Oxadiazole-2(3H)-thione, 5-phenyl-; 2-Phenyl-1,3,4-oxadiazole-5-thiol; 1,3,4-oxadiazole-2-thiol, 5-phenyl-; EINECS 221-103-9; 5-Phenyl-[1,3,4]oxadiazole-2-thiol; 2-Fenil-5-mercapto-1,3,4-ossadiazolo; CHEMBL1164316; 1,3,4-OXADIAZOLE-5-THIOL, 2-PHENYL-; FOHWXVBZGSVUGO-UHFFFAOYSA-N; 2-Fenil-5-mercapto-1,3,4-ossadiazolo [Italian]; 5-phenyl-1,3,4-oxadiazole-2-thione; 2-Phenyl-1,3,4--oxadiazol-5-thiol
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 178.21 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


